With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Eli Lilly’s retatrutide is under investigation in another six Phase III trials.

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, retatrutide, a first-in-class glucose-dependent insulinotropic polypeptide (GIP), ...